Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis.

RATIONALE Sarcoidosis is a granulomatous disease of unknown etiology, although M. tuberculosis may play a role in the pathogenesis. The traditional view holds that inflammation in sarcoidosis is compartmentalized to involved organs. OBJECTIVES To determine whether whole blood gene expression signatures reflect inflammatory pathways in the lung in sarcoidosis and whether these signatures overlap with tuberculosis. METHODS We analyzed transcriptomic data from blood and lung biopsies in sarcoidosis and compared these profiles with blood transcriptomic data from tuberculosis and other diseases. MEASUREMENTS AND MAIN RESULTS Applying machine learning algorithms to blood gene expression data, we built a classifier that distinguished sarcoidosis from health in derivation and validation cohorts (92% sensitivity, 92% specificity). The most discriminative genes were confirmed by quantitative PCR and correlated with disease severity. Transcript profiles significantly induced in blood overlapped with those in lung biopsies and identified shared dominant inflammatory pathways (e.g., Type-I/II interferons). Sarcoidosis and tuberculosis shared more overlap in blood gene expression compared with other diseases using the 86-gene signature reported to be specific for tuberculosis and the sarcoidosis signature presented herein, although reapplication of machine learning algorithms could identify genes specific for sarcoidosis. CONCLUSIONS These data indicate that blood transcriptome analysis provides a noninvasive method for identifying inflammatory pathways in sarcoidosis, that these pathways may be leveraged to complement more invasive procedures for diagnosis or assessment of disease severity, and that sarcoidosis and tuberculosis share overlap in gene regulation of specific inflammatory pathways.

[1]  R. Szubin,et al.  A novel method of gene transcript profiling in airway biopsy homogenates reveals increased expression of a Na+-K+-Cl- cotransporter (NKCC1) in asthmatic subjects. , 2001, Genome research.

[2]  D. Moller,et al.  Etiology of sarcoidosis. , 1997, Clinics in chest medicine.

[3]  G. McLennan,et al.  A case control etiologic study of sarcoidosis: environmental and occupational risk factors. , 2004, American journal of respiratory and critical care medicine.

[4]  D. James Occasional Survey: IMMUNOLOGY OF SARCOIDOSIS , 1966 .

[5]  Sharon Sanderson,et al.  Gene set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis. , 2010, American journal of respiratory and critical care medicine.

[6]  J. Grunewald,et al.  Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis. , 2001, American journal of respiratory and critical care medicine.

[7]  R. Crystal,et al.  Spontaneous release of interleukin 2 by lung T lymphocytes in active pulmonary sarcoidosis is primarily from the Leu3+DR+ T cell subset. , 1986, The Journal of clinical investigation.

[8]  R. Crystal,et al.  T lymphocytes compartmentalized on the epithelial surface of the lower respiratory tract express the very late activation antigen complex VLA-1. , 1988, Clinical immunology and immunopathology.

[9]  M. Rossman,et al.  Immunologic abnormalities in sarcoidosis. , 1980, Annals of internal medicine.

[10]  B. Balbi,et al.  Helper T-lymphocytes in pulmonary sarcoidosis. Functional analysis of a lung T-cell subpopulation in patients with active disease. , 1986, The American review of respiratory disease.

[11]  Virginia Pascual,et al.  A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. , 2008, Immunity.

[12]  V. Ferrans,et al.  Maintenance of granuloma formation in pulmonary sarcoidosis by T lymphocytes within the lung. , 1980, The New England journal of medicine.

[13]  H. Israel,et al.  Altered immunologic reactions in sarcoidosis. , 1954, Annals of internal medicine.

[14]  A. Sagone,et al.  In vitro observations on sarcoid lymphocytes and their correlation with cutaneous energy and clinical severity of disease. , 2015, The American review of respiratory disease.

[15]  Alan R. Dabney BIOINFORMATICS Classification of Microarrays to Nearest Centroids , 2022 .

[16]  R. Crystal,et al.  Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. , 1981, The Journal of clinical investigation.

[17]  R. Crystal,et al.  Spontaneous expression of the interleukin 2 receptor gene and presence of functional interleukin 2 receptors on T lymphocytes in the blood of individuals with active pulmonary sarcoidosis. , 1988, The Journal of clinical investigation.

[18]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[19]  R. Crystal,et al.  Compartmentalized activation of the interleukin 2 gene by lung T lymphocytes in active pulmonary sarcoidosis. , 1986, Journal of immunology.

[20]  D. James,et al.  Course and prognosis of sarcoidosis around the world. , 1974, The American journal of medicine.

[21]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[22]  K. Hirschhorn,et al.  IN-VITRO STUDIES OF LYMPHOCYTES FROM PATIENTS WITH SARCOIDOSIS AND LYMPHOPROLIFERATIVE DISEASES. , 1964, Lancet.

[23]  Virginia Pascual,et al.  An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis , 2010, Nature.

[24]  W. Roberts,et al.  Pulmonary Sarcoidosis: A Disease Characterized and Perpetuated by Activated Lung T-Lymphocytes , 1981 .

[25]  D. Moller Etiology of sarcoidosis. , 1997, Clinics in chest medicine.

[26]  Ramón Díaz-Uriarte,et al.  Gene selection and classification of microarray data using random forest , 2006, BMC Bioinformatics.

[27]  N. McElvaney,et al.  Role of IL-18 in CD4+ T Lymphocyte Activation in Sarcoidosis1 , 2000, The Journal of Immunology.

[28]  F. Askin,et al.  Mycobacterial catalase–peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis , 2005, The Journal of experimental medicine.

[29]  Sandya Liyanarachchi,et al.  Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. , 2009, American journal of respiratory and critical care medicine.

[30]  Yee Hwa Yang,et al.  Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids , 2007, Proceedings of the National Academy of Sciences.

[31]  D. James,et al.  A Correlation of in Vivo Delayed-Type Hypersensitivity with in Vitro Lymphocyte Transformation in Sarcoidosis , 1971 .

[32]  R. Crystal,et al.  Localization of the immune response in sarcoidosis. , 2015, The American review of respiratory disease.

[33]  B. Hudspith,et al.  Lack of immune deficiency in sarcoidosis: compartmentalisation of the immune response. , 1987, Thorax.

[34]  R. Crystal,et al.  Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. , 1985, The Journal of clinical investigation.

[35]  G. Hunninghake,et al.  Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis. , 2015, The American review of respiratory disease.

[36]  R. Winterbauer,et al.  Clinical interpretation of bilateral hilar adenopathy. , 1973, Annals of internal medicine.

[37]  Justine R. Smith,et al.  Hypothesis: sarcoidosis is a STAT1-mediated disease. , 2009, Clinical immunology.

[38]  D. James,et al.  Immunology of sarcoidosis. , 1966, The American journal of medicine.

[39]  H. Popper,et al.  Mycobacterial DNA in recurrent sarcoidosis in the transplanted lung – a PCR-based study on four cases , 2000, Virchows Archiv.

[40]  K. Rühle,et al.  Ia-like antigens on T-cells and their subpopulations in pulmonary sarcoidosis and in hypersensitivity pneumonitis. Analysis of bronchoalveolar and blood lymphocytes. , 1985, The American review of respiratory disease.

[41]  G. McLennan,et al.  Job and Industry Classifications Associated With Sarcoidosis in a Case–Control Etiologic Study of Sarcoidosis (ACCESS) , 2005, Journal of occupational and environmental medicine.

[42]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[43]  B. Balbi,et al.  Alveolar macrophage stimulation of T-cell proliferation in autologous mixed lymphocyte reactions. Role of HLA-DR antigens. , 2015, The American review of respiratory disease.

[44]  R. Crystal,et al.  Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis. , 1983, The New England journal of medicine.

[45]  A. Aggarwal,et al.  Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis , 2007, European Respiratory Journal.

[46]  R. Crystal,et al.  Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. , 1981, The New England journal of medicine.

[47]  M. Schwarz,et al.  Interstitial Lung Disease , 2003 .

[48]  Andy Liaw,et al.  Classification and Regression by randomForest , 2007 .

[49]  S. Kalams,et al.  Cellular Recognition of Mycobacterium tuberculosis ESAT-6 and KatG Peptides in Systemic Sarcoidosis , 2006, Infection and Immunity.